A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Trial Details
- NCT ID
- NCT06563505
- Phase
- PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Mosunetuzumab
- Zanubrutinib
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Patients must meet the following criteria for study entry:
- Histologically diagnosed marginal zone lymphoma (any subtypes)
- o Low grade or indolent B-cell lymphoma unclassifiable is also eligible
- Have received at least 1 prior treatment including CD20 monoclonal antibody
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →